Abstract:BACKGROUND In the past 10 years, significant progress has been made in understanding the pathogenic chain of events that causes Alzheimer's disease (AD). According to the most widely accepted concept, the production and aggregation of β-amyloid (Aβ) peptides play a critical role in AD. As a result, therapeutic intervention with these processes is the focus of intense research. The Aβ peptide is cleaved by the α-secretase, β-secretase, and γ-secretase enzymes in a region near the pathogenic amyloid precursor protein (APP) and mutations occurring site. METHODS In the current review, a complete picture of the risk factors behind AD has been investigated. Mutations involved in AD progression have also been screened in various studies. RESULTS Most of the mutations in the amyloid precursor protein (APP) can lead to the accumulation of APP oligomers in the brain, leading to AD. Several point mutations in APP can cause familial AD (FAD), including the Swedish mutation (K>M670/671N>L) and the A673>V mutation. The pathogenic A673>V mutation and Swedish mutation (M670>K/N671>L) are present in the same region of amyloid precursor protein (APP). However, the A673>T mutation has been shown to confer protection against AD. CONCLUSION More investigations are needed from geographically distinct regions on mutations associated with AD development and applications of nanomedicines for better management of the disease burden in the future. Nanotechnology-produced metal nanoparticles (NPs) have gotten much attention because of their wide range of uses in the medicinal and agricultural industries. Nanomedicine containing potential phytochemicals, including GX-50 and curcumin conjugated with NPs, maybe a potential candidate for treating AD.

Nanoneurotoxicity and Potential Nanotheranostics for Alzheimer's Disease.

Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

Emerging nanotechnology for Alzheimer's disease: From detection to treatment

Application of nanotechnology for diagnosis of Alzheimer's disease

Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease

Alzheimer's Disease; Mechanism, Mutations, and Applications of Nano-Medicine.

Advanced Nanomaterials for Modulating Alzheimer's Related Amyloid Aggregation

Nanomaterials Toward the Treatment of Alzheimer’s Disease:Recent Advances and Future Trends

Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview

Nanotechnology for Tau Pathology in Alzheimer's Disease

Emerging Nanotechnology for Treatment of Alzheimer's and Parkinson's Disease

Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease

Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

Nanotechnology for microglial targeting and inhibition of neuroinflammation underlying Alzheimer's pathology

Functional Nanomaterials for the Diagnosis of Alzheimer's Disease: Recent Progress and Future Perspectives

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer’s Disease

An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy.

Research Progress of Novel Inorganic Nanomaterials in the Diagnosis and Treatment of Alzheimer's Disease

Research Progress of Novel Inorganic Nanomaterials in the Diagnosis and Treatment of Alzheimer’s Disease

Advances in Alzheimer's disease control approaches via carbon nanotubes